Go Deep
Cytosorbents Corporation
Cytosorbents Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -27,533 | -0.5 | -12.84 | 4.93 | 289.83 |
| Oct 2026 | -30,022 | -0.7 | -17.25 | 4.93 | 389.28 |
| Oct 2026 | -33,866 | -0.9 | -20.81 | 4.93 | 470.29 |
| Oct 2026 | -34,755 | -0.9 | -22.32 | 4.93 | 504.42 |
| Oct 2026 | -34,854 | -0.9 | -22.45 | 4.93 | 506.01 |
| Oct 2026 | -36,430 | -1.0 | -25.22 | 4.93 | 567.29 |
Cytosorbents Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 9,633,000.0 | 8,864,000.0 | 9,234,000.0 | 9,485,000.0 |
| Net Profit | -4,417,000.0 | -5,129,000.0 | -5,497,000.0 | -3,170,000.0 |
| EPS | -1.4 | -1.6 | -1.8 | -1.0 |
Cytosorbents Corporation Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 37,063,000.0 | 35,595,000.0 | 31,084,953.0 | 29,359,910.0 | — |
| Net Profit | -8,198,000.0 | -20,719,000.0 | -29,246,760.0 | -32,812,583.0 | — |
| EPS | -2.6 | -7.6 | -13.0 | -14.9 | — |
Cytosorbents Corporation Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 44,182,000.0 | 47,372,000.0 | 52,956,322.0 | 63,231,530.0 | — |
| Total Liabilities | 38,279,000.0 | 36,265,000.0 | 29,475,108.0 | 27,856,557.0 | — |
| Total Equity | 5,903,000.0 | 11,107,000.0 | 23,481,214.0 | 35,374,973.0 | — |
Owes vs Owns
Cytosorbents Corporation owed $1.02 for every $1 it owned in Jun 2026, up from $0.44 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.02× | 0.87× | 0.77× | 0.56× | 0.44× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Cytosorbents Corporation Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 14.1%Receivables 17.1%Inventory 12.0%Fixed assets (tangible) 42.4%Intangible assets 7.3%Other assets 7.1%
How it's funded — Dec 2025
Short-term debt 1.2%Long-term debt 37.7%Payables 6.5%Other liabilities 41.2%Shareholders' equity 13.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 6.2 | 3.3 | 14.1 | 22.1 |
| Receivables | 7.5 | 7.3 | 6.1 | 5.7 |
| Inventory | 5.3 | 2.7 | 3.4 | 3.5 |
| Fixed assets (tangible) | 18.7 | 20.5 | 22.1 | 23.3 |
| Intangible assets | 3.2 | 3.7 | 3.9 | 4.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.1 | 9.8 | 3.4 | 4.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.5 | 0.5 | 2.5 | 0.1 |
| Long-term debt | 16.7 | 14.0 | 2.5 | 5.0 |
| Payables | 2.9 | 3.3 | 3.8 | 2.5 |
| Other liabilities | 18.2 | 18.5 | 20.6 | 20.2 |
| Shareholders' equity | 5.9 | 11.1 | 23.5 | 35.4 |
| Net tangible assets | 2.7 | 7.4 | 19.6 | 31.0 |
Cytosorbents Corporation Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -12,377,000.0 | -14,428,000.0 | -21,655,136.0 | -28,234,282.0 | — |
| Investing Activities | -415,000.0 | -669,000.0 | -936,236.0 | -6,455,576.0 | — |
| Financing Activities | 9,309,000.0 | 9,331,000.0 | 14,474,210.0 | 4,959,642.0 | — |